Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism

Journal of Pineal Research

Volumn 55, Issue 3, 2013, Pages 304-312

  Naskar, Amit ^a   Manivasagam, Thamilarasan ^a,b   Chakraborty, Joy ^a   Singh, Raghavendra ^a   Thomas, Bobby ^a,c   Dhanasekaran, Muralikrishnan ^a,d   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b ANNAMALAI UNIVERSITY   (India)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d AUBURN UNIVERSITY   (United States)

Author keywords

behavior; dendritic spines; L DOPA; MPTP; spine density

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; LEVODOPA; MELATONIN;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; DOPAMINE METABOLISM; DRUG POTENTIATION; GOLGI STAIN; LOW DRUG DOSE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PARKINSONISM; PRESERVATION; TISSUE SECTION;

BEHAVIOR; DENDRITIC SPINES; L-DOPA; MPTP; SPINE DENSITY;

ANIMALS; ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CORPUS STRIATUM; DENDRITES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LEVODOPA; MELATONIN; MICE; MICE, INBRED BALB C; MPTP POISONING; PARKINSON DISEASE, SECONDARY;

EID: 84883740339     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12076     Document Type: Article

References (64)

1. Villalba RM, Lee H, Smith Y,. Dopaminergic denervation and spine loss in the striatum of MPTP treated monkeys. Exp Neurol 2009; 215: 220-227.
2. McNeill TH, Brown SA, Rafols JA, et al. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 1988; 455: 148-152.
3. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005; 132: 741-754.
4. Zaja-Milatovic S, Milatovic D, Schantz AM, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson's disease. Neurology 2005; 64: 545-547.
5. Mitra N, Mohanakumar KP, Ganguly DK,. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6- tetrehydropyridine in mice. Brain Res Bull 1992; 28: 355-364.
6. Gerlach M, Riederer P,. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996; 103: 987-1041.
7. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson's disease models. Nat Neurosci 2006; 9: 251-259.
8. Cepeda C, Hurst RS, Altemus KL, et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 2001; 85: 659-670.
9. Garcia BG, Neely MD, Deutch AY,. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cereb Cortex 2010; 20: 2423-2432.
10. Birkmayer W, Hornykiewicz O,. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961; 73: 787-788.
11. Tintner R, Jankovic J,. Treatment options for Parkinson's disease. Curr Opin Neurol 2002; 15: 467-476.
12. Borah A, Mohanakumar KP,. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental Parkinsonism in rodents. J Pineal Res 2009; 47: 293-300.
13. Borah A, Mohanakumar KP,. Denervated, but not innervated striatum of parkinsonian rats is sensitive to 6-hydroxydopamine production in vivo following prolonged L-DOPA administration. Neurochem Int 2010; 56: 357-362.
14. Deutch AY, Colbran RJ, Winder DJ,. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007; 13: S251-S258.
15. Careceni T, Scigliana G, Mussico M,. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa. Neurology 1991; 41: 380-384.
16. Bowes SG, Clark PK, Leeman AL, et al. Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy. Br J Clin Pharmacol 1990; 30: 13-24.
17. Lees AJ,. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-1607.
18. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-777.
19. Khaldy H, Escames G, Leõn J, et al. Synergistic effects of melatonin and deprenyl against MPTP- induced mitochondrial damage and DA depletion. Neurobiol Aging 2003; 24: 491-500.
20. Acuña-Castroviejo D, Coto-Montes A, Gaia Monti M, et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60: 23-29.
21. Antolín I, Mayo JC, Sainz RM, et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002; 943: 163-173.
22. +) neurotoxicity in rats. Neurosci Lett 1998; 245: 61-64.
23. Lu KT, Ko MC, Chen BY, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem 2008; 56: 6910-6913.
24. Muralikrishnan D, Mohanakumar KP,. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-912.
25. +-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002; 32: 262-269.
26. Thomas B, Mohanakumar KP,. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004; 36: 25-32.
27. Saravanan KS, Sindhu KM, Mohanakumar KP,. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 2007; 42: 247-253.
28. Morgan WW, Nelson JF,. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res 2001; 921: 115-121.
29. Tapias V, Cannon JR, Greenamyre JT,. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res 2010; 88: 420-427.
30. Fredriksson A, Plaznik A, Sundström E, et al. MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol Toxicol 1990; 67: 295-301.
31. Weihmuller FB, Hadjiconstantinou M, Bruno JP,. Dissociation between biochemical and behavioral recovery in MPTP-treated mice. Pharmacol Biochem Behav 1989; 34: 113-117.
32. Weihmuller FB, Hadjiconstantinou M, Bruno JP,. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci Lett 1988; 85: 137-142.
33. Rao BSS, Desiraju T, Raju TR,. Neuronal plasticity induced by self-stimulation rewarding experience in rats-a study on alteration in dendritic branching in pyramidal neurons of hippocampus and motor cortex. Brain Res 1993; 627: 216-224.
34. Smith DL, Pozueta J, Gong B, et al. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci USA 2009; 106: 16877-16882.
35. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
36. Mena MA, Davila V, Bogaluvsky J, et al. A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol 1998; 54: 678-686.
37. Castro LM, Gallant M, Niles LP,. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005; 95: 1227-1236.
38. Imbesi M, Uz T, Dzitoyeva S, et al. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci Lett 2008; 439: 34-36.
39. Kim MJ, Kim HK, Kim BS, et al. Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats. J Pineal Res 2004; 37: 193-197.
40. Kilic E, Kilic U, Bacigaluppi M, et al. Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. J Pineal Res 2008; 45: 142-148.
41. Manda K, Ueno M, Anzai K,. Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: attenuation by melatonin pretreatment. J Pineal Res 2009; 46: 71-78.
42. Shin JY, Park HJ, Ahn YH, et al. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J Neurochem 2009; 111: 1042-1050.
43. Capitelli C, Sereniki A, Lima MM, et al. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008; 594: 101-108.
44. Joo WS, Jin BK, Park CW, et al. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. NeuroReport 1998; 9: 4123-4126.
45. Singhal NK, Srivastava G, Patel DK, et al. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 2011; 50: 97-109.
46. Itzhak Y, Martin JL, Black MD, et al. Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacology 1998; 37: 781-791.
47. van der Schyf CJ, Castagnoli K, Palmer S, et al. Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox Res 2000; 1: 261-269.
48. Lin CH, Huang JY, Ching CH, et al. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 2008; 44: 205-213.
49. Ingham CA, Hood SH, van Maldegem B, et al. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 1993; 93: 17-27.
50. Ingham CA, Hood SH, Taggart P, et al. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J Neurosci 1998; 18: 4732-4743.
51. Bamford NS, Robinson S, Palmiter RD, et al. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004; 24: 9541-9552.
52. 2+ not cAMP. Am J Physiol 1995; 269: E85-E90.
53. Escames G, Macías M, Leõn J, et al. Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. J Neuroendocrinol 2001; 13: 459-466.
54. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000; 23: S8-S19.
55. Ahlskog JE, Muenter MD,. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
56. Fasano C, Bourque MJ, Lapointe G, et al. Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology 2013; 67: 432-443.
57. Moriya T, Horie N, Mitome M, et al. Melatonin influences the proliferative and differentiative activity of neural stem cells. J Pineal Res 2007; 42: 411-418.
58. Chen HY, Hung YC, Chen TY, et al. Melatonin improves presynaptic protein, SNAP-25, expression and dendritic spine density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res 2009; 47: 260-270.
59. Niles LP, Armstrong KJ, Rinco'n Castro LM, et al. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci 2004; 5: 41.
60. García-Chávez D, González-Burgos I, Letechipía-Vallejo G, et al. Long-term evaluation of cytoarchitectonic characteristics of prefrontal cortex pyramidal neurons, following global cerebral ischemia and neuroprotective melatonin treatment, in rats. Neurosci Lett 2008; 448: 148-152.
61. González-Burgos I, Letechipía-Vallejo G, Lõpez-Loeza E, et al. Long-term study of dendritic spines from hippocampal CA1 pyramidal cells, after neuroprotective melatonin treatment following global cerebral ischemia in rats. Neurosci Lett 2007; 423: 162-166.
62. Crupi R, Mazzon E, Marino A, et al. Melatonin's stimulatory effect on adult hippocampal neurogenesis in mice persists after ovariectomy. J Pineal Res 2011; 51: 353-360.
63. Crupi R, Mazzon E, Marino A, et al. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res 2010; 49: 123-129.
64. Lundblad M, Picconi B, Lindgren H, et al. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004; 16: 110-123.